Episode Details
Back to EpisodesCLL and ASH 2025: CAR T-cell Therapy and Data on Vaccination and Cancer Screening
Episode 637
Published 3 months, 3 weeks ago
Description
Drs. Wierda and O’Brien discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.